MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Price & Overview

NASDAQ:MRVIUS56600D1072

Current stock price

3.69 USD
+0.01 (+0.27%)
At close:
3.69 USD
0 (0%)
After Hours:

The current stock price of MRVI is 3.69 USD. Today MRVI is up by 0.27%. In the past month the price increased by 19.81%. In the past year, price increased by 80.44%.

MRVI Key Statistics

52-Week Range1.95 - 4.105
Current MRVI stock price positioned within its 52-week range.
1-Month Range2.8 - 3.805
Current MRVI stock price positioned within its 1-month range.
Market Cap
948.588M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.28
Dividend Yield
N/A

MRVI Stock Performance

Today
+0.27%
1 Week
+5.43%
1 Month
+19.81%
3 Months
-0.54%
Longer-term
6 Months +8.21%
1 Year +80.44%
2 Years -55.00%
3 Years -73.24%
5 Years -90.52%
10 Years N/A

MRVI Stock Chart

MARAVAI LIFESCIENCES HLDGS-A / MRVI Daily stock chart

MRVI Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to MRVI. When comparing the yearly performance of all stocks, MRVI is one of the better performing stocks in the market, outperforming 87.04% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MRVI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MRVI. MRVI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRVI Earnings

On February 25, 2026 MRVI reported an EPS of -0.04 and a revenue of 49.87M. The company beat EPS expectations (44.7% surprise) and missed revenue expectations (-0.32% surprise).

Next Earnings DateMay 11, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.04
Revenue Reported49.866M
EPS Surprise 44.70%
Revenue Surprise -0.32%

MRVI Forecast & Estimates

17 analysts have analysed MRVI and the average price target is 4.42 USD. This implies a price increase of 19.78% is expected in the next year compared to the current price of 3.69.

For the next year, analysts expect an EPS growth of 34.21% and a revenue growth 10.81% for MRVI


Analysts
Analysts76.47
Price Target4.42 (19.78%)
EPS Next Y34.21%
Revenue Next Year10.81%

MRVI Groups

Sector & Classification

MRVI Financial Highlights

Over the last trailing twelve months MRVI reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -180% compared to the year before.


Income Statements
Revenue(TTM)185.74M
Net Income(TTM)-130.77M
Industry RankSector Rank
PM (TTM) N/A
ROA -16.97%
ROE -61.58%
Debt/Equity 1.49
Chartmill High Growth Momentum
EPS Q2Q%33.33%
Sales Q2Q%-11.83%
EPS 1Y (TTM)-180%
Revenue 1Y (TTM)-28.34%

MRVI Ownership

Ownership
Inst Owners77.1%
Shares257.07M
Float109.12M
Ins Owners5.16%
Short Float %8.72%
Short Ratio6.18

About MRVI

Company Profile

MRVI logo image Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 435 full-time employees. The company went IPO on 2020-11-20. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. The company serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Company Info

IPO: 2020-11-20

MARAVAI LIFESCIENCES HLDGS-A

10770 Wateridge Circle Suite 200, Suite 200

San Diego CALIFORNIA 92121 US

CEO: Carl Hull

Employees: 435

MRVI Company Website

MRVI Investor Relations

Phone: 13026587581

MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ

What does MARAVAI LIFESCIENCES HLDGS-A do?

Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 435 full-time employees. The company went IPO on 2020-11-20. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. The company serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.


Can you provide the latest stock price for MARAVAI LIFESCIENCES HLDGS-A?

The current stock price of MRVI is 3.69 USD. The price increased by 0.27% in the last trading session.


Does MRVI stock pay dividends?

MRVI does not pay a dividend.


How is the ChartMill rating for MARAVAI LIFESCIENCES HLDGS-A?

MRVI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the analyst forecast for MRVI stock?

17 analysts have analysed MRVI and the average price target is 4.42 USD. This implies a price increase of 19.78% is expected in the next year compared to the current price of 3.69.


What is the employee count for MRVI stock?

MARAVAI LIFESCIENCES HLDGS-A (MRVI) currently has 435 employees.


What is the outstanding short interest for MARAVAI LIFESCIENCES HLDGS-A?

The outstanding short interest for MARAVAI LIFESCIENCES HLDGS-A (MRVI) is 8.72% of its float.